Recently we demonstrated that prolonged administration of IFN-␥ prevented the development of GVHD in a MHC-mismatched murine BMT model. Treatment with IFN-␥ allowed the development of mature donorderived allo-tolerant immunocompetent cells in complete chimeric recipients. Here we present data on the pharmacodynamics of this cytokine-mediated protection against GVHD. Treatment with 50 000 U IFN-␥ twice weekly for a period of 5 weeks, starting at the day of BMT, was shown to be the optimal treatment protocol, resulting in complete prevention of GVHD-related mortality. Treatment during 1 week with a three-fold higher weekly dose of IFN-␥ (50 000 U six times) did not result in significantly improved survival. The start of IFN-␥ administration was a critical factor since a delay of 3 days from the time of BMT resulted in substantial GVHD-induced mortality. Furthermore, it was shown that IFN-␥ treatment inhibited the spontaneous and Con-A-induced proliferation of T cells at 7-14 days after BMT, which is the critical period for the initiation of acute GVHD. However, long-term survivors after IFN-␥ treatment showed a recovery of immunity in contrast to long-term survivors of saline-injected animals, as tested by Con-A responsiveness. It seems that injection of high dose IFN-␥ suppresses the response of potentially alloreactive donor T cells during what normally is the initiation phase of the GVH reaction (GVHR), resulting in the abrogation of GVHD.
cell types. During the GVH reaction (GVHR), several phases can be recognised. 9 ,10 IFN-␥, 11, 12 IL-2 13, 14 and IL-12 15, 16 are thought to play an important role during the initiation phase whereas pro-inflammatory cytokines such as IL-1 17 and TNF-␣ 18, 19 are mainly involved during the effector phase. Several investigators showed that by inhibition of the cytokine activity, using for example IL-1R antagonist 17 or anti-TNF-␣, 19 anti-IL-2R, 13 anti-IL-12 16 and anti-IFN-␥, 12, 20 GVHD could be mitigated. The time of availability of a given cytokine after BMT may be an important factor in GVHD development. It is thought that by interference in the cytokine-cascade shortly after BMT, GVHD may be mitigated. Sykes et al 26 demonstrated that GVHD could be prevented when recipient mice were treated with either IL-2 [21] [22] [23] [24] [25] or IL-12. We have demonstrated that treatment with IFN-␥ prevented GVHD in a fully H-2-mismatched BMT mouse model. 20 , 27 Here we report on pharmacodynamic studies carried out to determine the most effective treatment schedule and to find the optimal dose of IFN-␥. The possible effect of IFN-␥ on T cells of donor origin present in the host was studied by testing the proliferative capacity of spleen cells (SC) shortly after BMT.
Materials and methods

Animals
Bone marrow (BM) recipients were 12-to 25-week-old male and female C3H/Law (H-2 k ) mice with a defined conventional microflora. Sex-matched donors of the BM-graft were fully H-2-mismatched C57BL/Rij (H-2 b ) mice with a defined specified pathogen-free (SPF) microflora. Composition of these microflora is described elsewhere. 28 All animals were obtained from the gnotobiotic facility at the TNO Medical Biological Laboratory (TNO-MBL). To exclude the influence of changes in the composition of the microflora during the experiments, all recipient animals were housed, irradiated and transplanted under strict reverse isolation conditions. 28 All animals had free access to autoclaved food (AM-II food pellets; Hope Farms BV, Woerden, The Netherlands) and autoclaved acidified drinking water (pH 2.8).
BMT
The details of this murine BMT model have been described elsewhere. 20 Briefly, mice were lethally irradiated with 9.0 Gy TBI (Philips-Müller X-ray machine; Philips, Eindhoven, The Netherlands). After 1-5 h (day 0), mice were transplanted with 10 7 BM cells obtained from donor femora. BM cells were given by a single 0.5 ml injection in the tail vain. Radiation controls received neither BM cells nor SC.
Diagnosis of GVHD
GVHD was diagnosed by checking the animals twice daily for macroscopic signs, typical of GVHD. 29 GVHD was verified histopathologically in animals that died during the experiment, as well as in animals that were sacrificed at 120 days after BMT. Also, organs from animals of which the SC were used in the proliferation assays (see below) were analysed for GVHD. Briefly, the severity and the extent of the lesions were scored blind and graded 0 to 4. 30 From animals that died during the experiments, heart blood was microbiologically cultured to rule out death due to sepsis. Chimerism was tested in all long-term survivors by FACScan analysis using the donor-specific granulocyte marker GM1.2, as described before. 31 
Determination of optimal treatment schedule
Since administration of IFN-␥ is known to have toxic sideeffects, [32] [33] [34] we studied different dosing schedules to determine the optimal treatment schedule. Recombinant rat IFN-␥ was derived from a CHO-cell line and ligand purified as described elsewhere. 35 Dose finding: Three experimental groups (n ϭ 10 per group) were injected (i.p.) twice weekly with 10 000, 25 000 or 50 000 U IFN-␥/mouse respectively, up to 6 weeks after BMT, starting at day 0.
Treatment schedule: To determine the minimal effective treatment period, four experimental groups (n ϭ 10 per group) were compared. IFN-␥ was given twice weekly (i.p.; 50 000 U/mouse) for a period of 1, 3, 4 or 5 weeks. Treatment was started on day 0. We also investigated the time span from BMT to the start of IFN-␥ treatment which still resulted in optimal GVHD prevention. Four experimental groups of mice (n ϭ 5 per group) were compared to the above described group of 10 animals that had received twice weekly IFN-␥ (i.p.; 50 000 U/mouse) for a period of 5 weeks starting on day 0. The animals in these four groups were given 50 000 U IFN-␥ twice weekly for a period of 6 weeks, while treatment was started either on day 3, day 5, day 10 or day 14 after BMT. Additionally, we investigated whether a short course of more IFN-␥; ie six injections (i.p.) of 50 000 U IFN-␥ within 1 week, could also protect the animals from GVHD. Three experimental groups of mice (n ϭ 6 per group) in which treatment was started either at day 0, day 7 or day 10 after BMT were compared.
Effect of IFN-␥ treatment on mitogen responsiveness of chimeric SC
To test the proliferative capacity after IFN-␥ treatment, spontaneous as well as mitogen-induced proliferation of chimeric SC in two experimental groups of mice were compared. SC were obtained from transplanted animals which had received twice weekly injections of 50 000 U IFN-␥ during 6 weeks, starting at day 0. This protocol has been shown to be protective. 20 The proliferative capacity of SC of these animals was compared with that of SC obtained from animals that had been transplanted in a similar way as the IFN-␥-treated animals, but had been injected with saline (0.9%) only. SC obtained from syngeneic transplanted C3H/Law mice were used as controls at several time points after BMT.
At set time points, 10-13 mice were sacrificed and the SC were cultured for 48 h. Six wells of 96-wells round bottom plates (Costar 2595, Cambridge, MA, USA) were seeded with 5 × 10 4 SC/well. Half of the wells were supplemented with Con-A (Pharmacia, Uppsala, Sweden) to a final concentration of 10 g/ml. Cells were cultured using complete culture medium (Hepes-buffered RPMI 1640 (GIBCO, Glasgow, UK) supplemented with 10% FCS (Flow Laboratories, McLean, VA, USA), 100 U of penicillin G/ml and 100 g streptomycin/ml). Eighteen hours before harvesting, 1.0 Cu of 3 H-thymidine was added. Cultures were harvested on filters and label uptake was determined by liquid scintillation.
Statistics
Significance in survival and diarrhoea curves was determined using the Lee-Desu test. The Mann-Whitney U test was used to determine significant differences in proliferative responses. P values of less than 0.05 were considered to be significant.
Results
Dose finding
Increased percentages of diarrhoea (30%) were observed in animals which were treated twice weekly with a dose of 1 × 10 4 or 2.5 × 10 4 U IFN-␥. Animals treated with 5 × 10 4 U IFN-␥, during a period of 6 weeks, developed no diarrhoea (P Ͻ 0.05; Lee-Desu). GVHD-related mortality was prevented when the animals were treated with 5 × 10 4 U IFN-␥ resulting in significantly different survival curves (P Ͻ 0.05; Figure 1 ).
Treatment schedule
Macroscopic signs of GVHD could be completely prevented if the animals were treated for a period of at least 5 weeks, resulting in a 100% survival ( Figure 2 ). As shown in Figure 3 , treatment had to be started directly at BMT to obtain the maximal protective effect. Treatment with a short course of very high-dose IFN-␥ was shown not to be protective for GVHD (Figure 4) . (group III) U IFN-␥. All animals were treated for 6 weeks, starting on the day of BMT. Each group consisted of 10 animals. Survival was scored up to 120 days after BMT. Statistical significant differences in survival curves were calculated using the Lee-Desu test. 
Diagnosis of GVHD
In all animals that died during the experiments the cause of death was due to GVHD as was confirmed histopathologically (results not shown). No sepsis was observed in animals that died during the experiments. Testing of the bone marrow of long-term survivors at day 120 after BMT for chimerism showed that all granulocytes were of donor origin (data not shown). Irradiated, non-transplanted control animals died within 14 days after BMT.
Effect of IFN-␥ treatment on mitogen responsiveness
Data on the spontaneous proliferative responses of SC are shown in Figure 5a . Significantly lower responses were observed in cultures of SC from IFN-␥ treated animals as compared to SC from saline-injected animals, obtained at day 7, day 10 and day 14 after BMT; they were not significantly different from the data of SC derived from syngeneic transplanted animals. The proliferative responses of SC after Con-A stimulation are given in Figure 5b . At day 7 after BMT, SC of IFN-␥-treated animals showed significantly lower responses as compared to SC of control animals; they were similar to the response of SC of recipients of syngeneic BM. Proliferative responses to Con-A increased rapidly in SC of syngeneic recipients from day 10 onwards as compared to Con-A responses of SC of the animals which received mismatched BM, reflecting the fast C3H/Law mice were given 10 7 C57BL/Rij BMC and injected with saline (white bars; n ϭ 98) or treated with IFN-␥ (shaded bars; n ϭ 108). At indicated time points after BMT, mice were sacrificed (day 5, day 10, day 23 and day 56: n ϭ 12; day 7: n ϭ 13; day 14 and day 19: n ϭ 16; day 119: n ϭ 5 or n ϭ 15 for saline-injected and IFN-␥-treated animals, respectively). The SC were cultured for 24 h. 5 × 10 4 SC were seeded per well using 96-wells round bottom culture plates either alone (a), or supplemented with 10 g Con-A per ml (b). Eighteen hours before harvesting, 1.0 Cu of 3 H-labelled thymidine ( 3 H-Thy) was added to each well and label uptake was measured using a gamma counter. Animals which had received a syngeneic graft (black bars; n ϭ 20; four animals per time point) served as the control group for haemopoietic recovery after BMT). Results are expressed as the mean counts (Ϯs.e.m.) of 3 H-Thy incorporation per 5 × 10 4 SC derived from individual triplicate samples. Inter-individual variation was less than 15%. (a) Significantly lower amounts of spontaneous proliferation were found at day 7 (P Ͻ 0.01; Mann-Whitney U), day 10 (P Ͻ 0.05) and day 14 (P Ͻ 0.05) after BMT in SC of IFN-␥-treated or syngeneic transplanted animals as compared to saline injected animals. (b) Significantly lower amounts of Con-A-induced proliferation were found at day 7 after BMT in SC derived from IFN-␥-treated or syngeneic transplanted animals (P Ͻ 0.05; Mann-Whitney U) as compared to saline-injected animals. At day 56 and day 119 after BMT, significantly lower numbers of Con-A-activated cells were found from SC of saline injected animals as compared to IFN-␥-treated animals (P Ͻ 0.05 and P Ͻ 0.01, respectively). The data were obtained from two experiments. (ND, not done; **P Ͻ 0.01, *P Ͻ 0.05).
immunological recovery in the former group. However, at 56 days and 119 days after BMT, SC from IFN-␥-treated animals showed significantly higher Con-A responses as compared to SC of saline injected animals (P Ͻ 0.05 and P Ͻ 0.01, respectively). This indicates that the immunological recovery in long-term survivors of saline-injected animals is hampered for a prolonged period of time, in contrast to the IFN-␥-treated animals.
Discussion
The results show that 50 000 U IFN-␥/mouse, twice weekly, has to be given for at least 5 weeks in order to completely prevent signs and symptoms of GVHD and GVHD-related mortality (Figures 1 and 2) . It is known that cytokines play an important role in the pathogenesis of acute GVHD. [6] [7] [8] [9] Recent data suggest that the time period 20, 25, 26, 36 as well as the site of production, ie locally or systemically, [37] [38] [39] of cytokines are important factors in inflammatory disease development. Treatment with antibodies directed against pro-inflammatory cytokines, such as IL-1 and TNF-␣, which play a major role during later stages of GVHD, was shown to be protective in parent into F 1 (P→F 1 ) BMT models, 17, 19 but ineffective when applied after fully MHC-mismatched BMT. 40, 41 Inhibition of cytokines which play a role during the initiation phase of GVHD, using antibodies against IL-2R, 13 IFN-␥ 12 or IL-12 15, 16 appeared to be very promising. The rationale behind these studies was that suppression of cytokine production would inactivate T cells during the initiation phase of GVHD development. Moreover, the adverse effects of IFN-␥, 12 IL-2 14 or IL-12 16 administration on GVHD development supported this hypothesis. However, most of these data were obtained in P→F 1 models and by (co)-injections of mature SC.
The effects of IL-12 and IFN-␥ on mature T cells are not comparable with their effects on (precursor) T cells present after BMT. 20, 24, [42] [43] [44] Using a completely H-2-mismatched murine BMT model in which BM cells are transplanted after lethal irradiation of the recipient, injections of IL-2, [21] [22] [23] [24] [25] IFN-␥ 20,27 and IL-12 26 were shown to be protective against GVHD. Sykes and co-workers 25, 26 demonstrated the association of GVHD with a peak production of IFN-␥ at days 4-5, which is in accordance with our own findings of an IFN-␥ peak at days 7-10 post BMT. 20, 27 It was concluded that the protective effect of IL-2 was independent of NK cell or LAK cell activity 22 and based on the selective suppression of CD4 ϩ Th 1 -like cells 23, 25 after the first week following BMT. Sykes and co-workers observed in their studies with IL-2 an expansion of a CD3 ϩ CD4 Ϫ CD8 Ϫ cell population at days 3-4 after BMT. 24 The effect of IL-12 is probably indirect and may result from a very high but short-lived peak of IFN-␥ production followed by a decrease of IFN-␥ production from day 4 onwards; it was also accompanied by the expansion of a CD3 ϩ CD4 Ϫ CD8 Ϫ cell population. 26 Previously, we documented that exogenously administered IFN-␥ inhibited the endogenous production of IFN-␥ by Th 1 -like cells during the initiation phase of GVHD, ie in the second week after BMT. 20 Here we report that during the second week after BMT the spontaneous proliferation of SC derived from IFN-␥-treated animals is as low as in SC of recipients of a syngeneic BM graft (Figure 5a ). Similar suppression of proliferation of SC has been described by others after administration of IL-2 [23] [24] [25] or IL-12. 26 It was essential in all these 'cytokine-based' models that treatment had to be started at BMT in order to obtain the maximal protective effect [20] [21] [22] [23] [24] [25] [26] [27] (Figure 3 ). The administration of IFN-␥ from day 2 onwards had no effect, as shown by Szebeni, 25 which is in accordance with the findings in this study. It is our opinion that an induced peak of IFN-␥ production shortly after BMT results in a decreased effect on polyclonal triggering of T cells during the initiation phase of GVHD.
IFN-␥ treatment only effects marginally the total number of T cells that could be activated after Con-A stimulation shortly after BMT (Figure 5b ) as compared to saline injected or syngeneic transplanted animals. This indicates that the immunological potential of these cells is not affected shortly after BMT. However, the response found in SC of saline-injected animals was severely suppressed during a prolonged period of time after BMT, whereas the SC of IFN-␥-treated animals showed comparable levels of activation as syngeneic transplanted animals after 56 days after BMT. This suggests that IFN-␥ did not prevent the outgrowth of immunologically competent T cells. 46, 47 These cells are generated after BMT across fully MHC mismatched barriers 48 and are non-specific inhibitors of the proliferative responses of T and B cells. 46, 49, 50 To obtain a complete protection against GVHD it is necessary to continue the IFN-␥ administration for at least 5 weeks. This finding seems to contrast the (partial) protective effect (up to 40%) of a single administration of IL-12. 26 However, in an earlier study we showed also that a single very high dose (500 000 U) of IFN-␥ was protective in 80% of the cases. 20 IFN-␥ 32-34 and IL-2 51-53 as well as IL-12 26 have some serious (acute) side-effects when applied in high doses. Its applicability in patients is questionable since preliminary data in non-human primates showed that a single administration of a very high dose of IFN-␥ caused severe sideeffects (unpublished observations), while similar observations were made in patients given a high dose of IL-2. 52, 53 Although the effects of IL-2, IL-12 and IFN-␥ on different cell types are difficult to distinguish, it is our opinion that the presence of high levels of IFN-␥ immediately after BMT is crucial for the prevention of GVHD. Whereas IL-2 and IL-12 are priming cytokines for the production IFN-␥, 54 the latter seems, according to our findings, to act as a self-perpetuating cytokine. The presence of IFN-␥ at high levels leads to a transient but critical inactivity of CD4 ϩ Th 1 cells.
